MFP enters the second half of July with a strong price run and its first meaningful analyst coverage — a combination that gives the stock fresh visibility at an interesting moment.
The week's headline is Oppenheimer's initiation. Analyst Ian Zaffino assigned an Outperform rating on July 15 with a $50 price target. That target sits roughly 15% above the current close of $43.50 and implies the Street's first formal bull case on the name. The lone prior consensus rating was a hold, carrying a $45 mean target — Oppenheimer's entry lifts both the tone and the ceiling. For a stock that only recently cleared the $40 level, that framing matters.
The price action supports the timing. MFP gained nearly 19% over the past week, reaching $43.50 — a move substantial enough to catch attention but not yet stretched toward the new target. The daily gain of around 2% on July 14 suggests momentum is still constructive rather than exhausted. Context from the prior earnings print reinforces the direction: a Q2 beat drove an 8.2% rally in late May, with revenue up 12% year-over-year to $187 million and operating margins expanding 140 basis points. Automation and cost discipline were credited, alongside demand in plant-based protein segments and international growth. With the next earnings event scheduled for August 27, that fundamental backdrop will soon face another test.
The lending market offers no complications for either side of the trade. Borrow availability is exceptionally loose — more than six shares remain available to lend for every one currently borrowed, with availability running at roughly 610%. That reading has actually eased further this week from a low of around 400% seen on July 9, meaning the pool of lendable shares has expanded rather than contracted alongside the price rally. Cost to borrow has crept up modestly — from 0.47% at the start of the week to 0.68% by July 14 — but remains firmly in "low" territory. Nothing in the borrow market suggests bears are building meaningful pressure or that shorts face any squeeze dynamic.
Overall, the positioning picture is straightforward: a fundamentally improving business, a fresh initiating buy, and a borrow market that places no constraints on either direction. The next inflection point worth watching is the August 27 earnings print — specifically whether margin expansion and plant-based demand trends hold their trajectory into the second half, and whether Oppenheimer's $50 target begins drawing incremental Street coverage behind it.
See the live data behind this article on ORTEX.
Open MFP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
